The changing etiology of liver cancer: A comparative study of global and Chinese burden trends from hepatitis dominance to metabolic risks (1990–2021) and forecasts to 2035

Abstract

Background and aims: Liver cancer remains a major global health burden with a complex and shifting epidemiology. While viral hepatitis continues to drive significant morbidity, metabolic risk factors are increasingly contributing to the incidence of liver cancer. Utilizing data from the Global Burden of Disease (GBD) Study 2021, this analysis examines China’s incidence, prevalence, and age-standardized disability-adjusted life year (DALY) rates for liver cancer from 1990 to 2021, comparing these trajectories against global and regional patterns. This study further analyzed the correlations between liver cancer burden and socioeconomic development, aiming to provide evidence for targeted intervention strategies and health policy formulation.

Methods: This study utilized data from the Global Burden of Disease Study 2021 to analyze the burden of liver cancer from 1990 to 2021 across 204 countries and territories. Standardized methodologies were used to estimate prevalence, incidence and DALYs. The Socio-demographic index (SDI) was applied to evaluate Socioeconomic disparities. Joinpoint regression was employed to analyze temporal trends, and age-period-cohort modeling was applied to estimate drivers of disease burden. Age-standardized rates were projected to 2035 using statistical modeling techniques.

Results: Globally, the absolute number of liver cancer cases increased continuously, whereas age-standardized rates declined from 1990 to 2021. Prevalent cases increased by 113.7% (from 345,912.7 to 739,299.5), incident cases increased by 116.2% (from 244,689.4 to 529,202.5), and total DALYs grew by 70.6% (from 7,553,666.8 to 12,887,652.4); the age-standardized DALY rate (ASDR) declined with an estimated annual percentage change (EAPC) of −0.6 (95% CI –0.72 to −0.48). Hepatitis B-related DALYs decreased significantly, while non-alcoholic steatohepatitis (NASH) and alcohol-related cases increased. China achieved marked reductions in age-standardized rates: the age-standardized incidence rate (ASIR) decreased from 10.6 to 9.5 per 100,000 (EAPC –0.28, 95% CI –0.42 to −0.13), and the ASDR fell from 334.5 to 239.9 per 100,000 (EAPC –1.16, 95% CI –1.34 to −0.98), especially in hepatitis B, though metabolic-related burdens grew. Prevalent cases in China doubled (from 132,779.2 to 265,539.4) and incident cases rose by 104.0% (from 96,434.3 to 196,636.6). Gender and age disparities were evident, with males and older adults bearing higher burdens. High-income regions saw rising metabolic-related rates, whereas low- and middle-income areas faced persistent viral hepatitis burdens. Projections suggest a continued rise in metabolic-related liver cancer globally, with NASH-related rates accelerating fastest in China, underscoring the need for dual preventive strategies targeting both infection and lifestyle factors.

Conclusions: The global burden of liver cancer is undergoing an epidemiological transition, marked by declining viral hepatitis-related rates but rising metabolic- and alcohol-related cases. Significant reductions in age-standardized rates were observed in China, though absolute case number increased. Socioeconomic and geographic disparities persist, with high-income regions facing growing metabolic burdens. Future trends emphasize the need for integrated strategies addressing both infectious and lifestyle-related risk factors.

Keywords

Etiology / Liver cancer / Global burden trends / Disability-adjusted life years (DALYs) / Risk factor

References

[1] GBD 2021 Causes of Death Collaborators. Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990—2021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet. 2024; 403:2100-2132. https://doi.org/10.1016/S0140—6736(24)00367—2.

[2] Chang J, Ajmera V, Fowler KJ, Burgoyne A. Etiologies of cirrhosis by ethnicities of patients with hepatocellular carcinoma. J Clin Oncol. 2023; 41:515.

[3] Hwang SY, Danpanichkul P, Agopian V, et al. Hepatocellular carcinoma: updates on epidemiology, surveillance, diagnosis and treatment. Clin Mol Hepatol. 2025; 31(Suppl):S228-S254. https://doi.org/10.3350/cmh.2024.0824.

[4] Jiang Z, Zeng G, Dai H, et al. Global, regional and national burden of liver cancer 1990—2021: a systematic analysis of the global burden of disease study 2021. BMC Public Health. 2025; 25:931. https://doi.org/10.1186/s12889—025—22026—6.

[5] Qin Y, Tang C, Li J, Gong J. Liver cancer in China: the analysis of mortality and burden of disease trends from 2008 to 2021. BMC Cancer. 2024; 24:594. https://doi.org/10.1186/s12885—024—12334—2.

[6] Tan EY, Danpanichkul P, Yong JN, et al. Liver cancer in 2021: Global Burden of Disease study. J Hepatol . 2025; 82:851-860. https://doi.org/10.1016/j.jhep.2024.10.031.

[7] Liu C, Yu J. Global inequality in the burden of hepatitis B from 1990 to 2021: findings from the global burden of disease study 2021: letter to the editor on “Comprehensive approach to controlling chronic hepatitis B in China”. Clin Mol Hepatol. 2025; 31:e134-e136. https://doi.org/10.3350/cmh.2024.1085.

[8] Danpanichkul P, Duangsonk K, Chen VL, et al. Global burden of HBV—related liver disease: primary liver cancer due to chronic HBV infection increased in over one—third of countries globally from 2000 to 2021. Hepatology. 2025; 82:1274-1286. https://doi.org/10.1097/HEP.0000000000001260.

[9] Huang DQ, Singal AG, Kono Y, Tan DJH, El—Serag HB, Loomba R. Changing global epidemiology of liver cancer from 2010 to 2019: NASH is the fastest growing cause of liver cancer. Cell Metab. 2022; 34:969-977(e2). https://doi.org/10.1016/j.cmet.2022.05.003.

[10] Tan DJH, Setiawan VW, Ng CH, et al. Global burden of liver cancer in males and females: changing etiological basis and the growing contribution of NASH. Hepatology. 2023; 77:1150-1163. https://doi.org/10.1002/hep.32758.

[11] Shan S, Zhao X, Jia J. Comprehensive approach to controlling chronic hepatitis B in China. Clin Mol Hepatol. 2024; 30:135-143. https://doi.org/10.3350/cmh.2023.0412.

[12] Xing Q, Li J, Dong X, et al. Socioeconomics and attributable etiology of primary liver cancer, 1990—2019. World J Gastroenterol . 2022; 28:2361-2382. https://doi.org/10.3748/wjg.v28.i21.2361.

[13] Xiao S, Xie W, Zhang Y, Lei L, Pan Y. Changing epidemiology of cirrhosis from 2010 to 2019: results from the Global Burden Disease study 2019. Ann Med. 2023; 55:2252326. https://doi.org/10.1080/07853890.2023.2252326.

[14] GBD 2021 Forecasting Collaborators. Burden of disease scenarios for 204 countries and territories, 2022—2050: a forecasting analysis for the Global Burden of Disease Study 2021. Lancet. 2024; 403:2204-2256. https://doi.org/10.1016/S0140—6736(24)00685—8.

[15] GBD 2021 Diseases and Injuries Collaborators. Global incidence, prevalence, years lived with disability (YLDs), disability—adjusted life—years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990—2021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet. 2024; 403:2133-2161. https://doi.org/10.1016/S0140—6736(24)00757—8.

[16] GBD 2021 Demographics Collaborators. Global age—sex—specific mortality, life expectancy, and population estimates in 204 countries and territories and 811 subnational locations, 1950—2021, and the impact of the COVID—19 pandemic: a comprehensive demographic analysis for the Global Burden of Disease Study 2021. Lancet. 2024; 403:1989-2056. https://doi.org/10.1016/S0140—6736(24)00476—8.

[17] GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990—2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020; 396:1204-1222. https://doi.org/10.1016/S0140—6736(20)30925—9.

[18] Rong J, Wang X, Cheng P, Li D, Zhao D. Global, regional and national burden of depressive disorders and attributable risk factors, from 1990 to 2021: results from the 2021 Global Burden of Disease study. Br J Psychiatry. 2025; 227:688-697. https://doi.org/10.1192/bjp.2024.266.

[19] Li N, Xu Y, Xiao X, Ding Z, Sun C, Zhang Q. Long—term trends in the burden of asthma in China: a joinpoint regression and age—period—cohort analysis based on the GBD 2021. Respir Res. 2025; 26:56. https://doi.org/10.1186/s12931—025—03135—7.

[20] Kim HJ, Chen HS, Byrne J, Wheeler B, Feuer EJ. Twenty years since Joinpoint 1.0: two major enhancements, their justification, and impact. Stat Med. 2022; 41:3102-3130. https://doi.org/10.1002/sim.9407.

[21] Kim HJ, Luo J, Chen HS, et al. Improved confidence interval for average annual percent change in trend analysis. Stat Med. 2017; 36:3059-3074. https://doi.org/10.1002/sim.7344.

[22] Yip TC, Wong GL. Transforming the landscape of liver cancer detection and care. Nat Rev Gastroenterol Hepatol. 2025; 22:86-87. https://doi.org/10.1038/s41575—024—01018—8.

[23] Wang Y, Han X, Zhang X, et al. Global burden of alcohol—associated liver disease across 204 Countries, 1990—2021: GBD 2021 findings. Liver Int. 2025; 45:e70283. https://doi.org/10.1111/liv.70283.

[24] Zhang S, Cui F. Global progress, challenges and strategies in eliminating public threat of viral hepatitis. Infect Dis Poverty. 2025; 14:9. https://doi.org/10.1186/s40249—025—01275—y.

[25] Zhang L, Wang T, Zhou S, Li S, Mo T, Wu S. Update on the global burden of acute viral hepatitis in 2021: addressing health inequalities. Front Public Health. 2025; 13:1580863. https://doi.org/10.3389/fpubh.2025.1580863.

[26] Chen Q, Huang S, Peng J, et al. The burden of hepatitis B and C in Asia, 1990—2019: an update analysis from the Global Burden of Disease Study 2019. Liver Int. 2025; 45:e70004. https://doi.org/10.1111/liv.70004.

[27] Al Ta’ani O, Al—Ajlouni Y, Jagdish B, et al. Examining the evolving landscape of liver cancer burden in the United States from 1990 to 2019. BMC Cancer . 2024; 24:1098. https://doi.org/10.1186/s12885—024—12869—4.

[28] Wang D, Tan M, Touch S, et al. Burden of disease and risk factors for primary liver cancer by etiology in the United States, 1990—2021: results from the Global Burden of Disease study, 2021. Ann Hepatol. 2025; 30:101906. https://doi.org/10.1016/j.aohep.2025.1.

[29] Gan C, Yuan Y, Shen H, et al. Liver diseases: epidemiology, causes, trends and predictions. Signal Transduct Targeted Ther . 2025; 10:33. https://doi.org/10.1038/s41392—024—02072—z.

[30] Yang S, Deng Y, Zheng Y, et al. Burden, trends, and predictions of liver cancer in China, Japan, and South Korea: analysis based on the Global Burden of Disease Study 2021. Hepatol Int. 2025; 19:441-459. https://doi.org/10.1007/s12072—024—10763—6.

[31] Huang DQ, El—Serag HB, Loomba R. Global epidemiology of NAFLD—related HCC: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2021; 18:223-238. https://doi.org/10.1038/s41575—020—00381—6.

[32] Younossi Z, Anstee QM, Marietti M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2018; 15:11-20. https://doi.org/10.1038/nrgastro.2017.109.

[33] Rumgay H, Arnold M, Ferlay J, et al. Global burden of primary liver cancer in 2020 and predictions to 2040. J Hepatol. 2022; 77:1598-1606. https://doi.org/10.1016/j.jhep.2022.08.021.

[34] Li Y, Ou Z, Yu D, et al. The trends in death of primary liver cancer caused by specific etiologies worldwide: results from the Global Burden of Disease Study 2019 and implications for liver cancer management. BMC Cancer. 2023; 23:598. https://doi.org/10.1186/s12885—023—11038—3.

[35] Liu Y, Zheng J, Hao J, et al. Global burden of primary liver cancer by five etiologies and global prediction by 2035 based on global burden of disease study 2019. Cancer Med. 2022; 11:1310-1323. https://doi.org/10.1002/cam4.4551.

[36] Alberts CJ, Clifford GM, Georges D, et al. Worldwide prevalence of hepatitis B virus and hepatitis C virus among patients with cirrhosis at country, region, and global levels: a systematic review. Lancet Gastroenterol Hepatol. 2022; 7:724-735. https://doi.org/10.1016/S2468—1253(22)00050—4.

[37] Veracruz N, Gish RG, Cheung R, Chitnis AS, Wong RJ. Global trends and the impact of chronic hepatitis B and C on disability—adjusted life years. Liver Int. 2022; 42:2145-2153. https://doi.org/10.1111/liv.15347.

[38] Su S, Wong WC, Zou Z, et al. Cost—effectiveness of universal screening for chronic hepatitis B virus infection in China: an economic evaluation. Lancet Global Health. 2022; 10:e278-e287. https://doi.org/10.1016/S2214—109X(21)00517—9.

[39] Yue T, Zhang Q, Cai T, et al. Trends in the disease burden of HBV and HCV infection in China from 1990—2019. Int J Infect Dis . 2022; 122:476-485. https://doi.org/10.1016/j.ijid.2022.06.017.

[40] Li S, Li S, Guan L, et al. Burden of NASH related liver cancer from 1990 to 2021 at the global, regional, and national levels. Front Nutr . 2025; 12:1510563. https://doi.org/10.3389/fnut.2025.1510563.

[41] Li Z, Yang N, He L, et al. Estimates and trends of the global burden of NASH—related liver cancer attributable to high fasting plasma glucose in 1990—2019: analysis of data from the 2019 Global Burden of Disease Study. Diabetol Metab Syndr. 2023; 15:6. https://doi.org/10.1186/s13098—022—00976—w.

[42] Cabibbo G, Celsa C, Rimassa L, et al. Navigating the landscape of liver cancer management: study designs in clinical trials and clinical practice. J Hepatol. 2024; 80:957-966. https://doi.org/10.1016/j.jhep.2024.01.018.

[43] Zheng J, Zhao L, Dong J, et al. The role of dietary factors in nonalcoholic fatty liver disease to hepatocellular carcinoma progression: a systematic review. Clin Nutr. 2022; 41:2295-2307. https://doi.org/10.1016/j.clnu.2022.08.018.

[44] Kanda T, Goto T, Hirotsu Y, Masuzaki R, Moriyama M, Omata M. Molecular mechanisms: connections between nonalcoholic fatty liver disease, steatohepatitis and hepatocellular carcinoma. Int J Mol Sci. 2020; 21. https://doi.org/10.3390/ijms21041525.

[45] Welch HG, Sharp SM, Gottlieb DJ, Skinner JS, Wennberg JE. Geographic variation in diagnosis frequency and risk of death among Medicare beneficiaries. JAMA. 2011; 305:1113-1118. https://doi.org/10.1001/jama.2011.307.

[46] Reddy KR, Mclerran D, Marsh T, et al. Incidence and risk factors for hepatocellular carcinoma in cirrhosis: the multicenter hepatocellular carcinoma early detection strategy (HEDS) study. Gastroenterology. 2023; 165:1053-1063. https://doi.org/10.1053/j.gastro.2023.06.027.